IRLAB-A.ST Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 04:32):

Stats
Today's Volume	4 677.00
Average Volume	88 105.00
Market Cap	585.21M
EPS	SEK0 ( 2024-02-06 )
Next earnings date	( SEK0 ) 2024-05-08
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-3.33
ATR14	SEK0.0890 (0.79%)

Volume Correlation

Long: -0.11 (neutral)

Short: 0.25 (neutral)

Signal:(57.247) Neutral

IRLAB Therapeutics AB Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

IRLAB Therapeutics AB Correlation - Currency/Commodity

0.70
( moderate )

0.63
( weak )

0.00
( neutral )

0.62
( weak )

-0.09
( neutral )

-0.43
( neutral )

IRLAB Therapeutics AB Financials

Annual	2023
Revenue:	SEK5.68M
Gross Profit:	SEK-180.13M (-3 172.46 %)
EPS:	SEK-3.43

FY	2023
Revenue:	SEK5.68M
Gross Profit:	SEK-180.13M (-3 172.46 %)
EPS:	SEK-3.43

FY	2022
Revenue:	SEK61.14M
Gross Profit:	SEK-111.23M (-181.94 %)
EPS:	SEK-2.20

FY	2021
Revenue:	SEK207.78M
Gross Profit:	SEK0.00 (0.00 %)
EPS:	SEK0.494

Financial Reports:

No articles found.

IRLAB Therapeutics AB

IRLAB Therapeutics AB (publ) develops drugs for the treatment of Parkinson's disease. The company develops Mesdopetam that is in phase IIb/III clinical studies for the treatment of dyskinesia; and Pirepemat, which is in phase IIb clinical trial for the treatment of Postural dysfunction. Its preclinical stage products include IRL942 and 1009 research programs for the treatment of neurodegenerative disorders and ageing; and IRL757 to treat apathy in neurological diseases. In addition, the company develops P003, a research project that develops drugs for the treatment of newly diagnosed Parkinson's disease. IRLAB Therapeutics AB (publ) was incorporated in 2013 and is based in Gothenburg, Sweden.